BC Innovations | Jun 4, 2019
Distillery Therapeutics

Mitochondria-targeted lonidamine for lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Cell culture and mouse studies suggest mitochondria-targeted lonidamine could help treat lung cancer. In two human lung cancer cell lines, lonidamine -- a generic inhibitor of aerobic glycolysis in...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest phenformin could help treat PTEN-deficient T cell ALL. In three mouse PTEN-deficient T cell ALL cell lines, phenformin inhibited growth with...
BC Innovations | Aug 16, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the...
BC Innovations | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Mitochondrial complex 1 (MC-1)

Endocrine/metabolic disease INDICATION: Mitochondrial disease Patient sample and cell culture studies identified prodrugs of succinate that could help treat Leigh syndrome and other mitochondrial diseases caused by MC-1 deficiency. Chemical synthesis of succinate prodrugs and...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Mitochondrial complex 1 (MC-1)

Cancer INDICATION: Pancreatic cancer In vitro, cell culture and mouse studies identified a metformin-based MC-1 inhibitor that could help treat pancreatic ductal adenocarcinoma (PDAC). Chemical synthesis and testing in a human PDAC cell line of...
BC Innovations | Apr 21, 2016
Distillery Therapeutics

Therapeutics: Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1); AMP-activated protein kinase (AMPK); mitochondrial complex 1 (MC

Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Patient sample, cell culture and mouse studies suggest inhibiting SLC2A1 , AMPK or MC-1 could help treat T cell ALL. Levels of the glucose transporter SLC2A1 were higher in T...
BC Week In Review | Nov 4, 2013
Clinical News

Flurpiridaz F 18 injection: Preliminary Phase III data

Preliminary data from an open-label, international Phase III trial in 740 patients with suspected or known CAD showed that PET myocardial perfusion imaging (MPI) with flurpiridaz F 18 met the co-primary endpoint of superior sensitivity...
BC Extra | Oct 30, 2013
Clinical News

Lantheus reports Phase III data for imaging agent

Lantheus Medical Imaging Inc. (North Billerica, Mass.) reported data on Tuesday from a Phase III trial evaluating PET myocardial perfusion imaging (MPI) with the company's flurpiridaz F 18 injection to diagnose coronary artery disease (CAD)...
BC Week In Review | May 6, 2013
Clinical News

Flurpiridaz F-18 injection: Phase III ongoing

Lantheus Medical said that, based on an interim analysis, it will proceed with an open-label, international Phase III trial comparing PET myocardial perfusion imaging (MPI) with flurpiridaz F-18 to single photon emission computed tomography (SPECT)...
BC Innovations | Feb 9, 2012
Targets & Mechanisms

Going viral in Parkinson's disease

University of Cambridge researchers have fused a virus-derived peptide that crosses the blood brain barrier with a neuroprotective RNA to generate a conjugate that can be delivered noninvasively to the brain in Parkinson's disease models....
Items per page:
1 - 10 of 14